Prescription Digital Therapeutics Patents: Leaders & Trends 2026
Prescription Digital Therapeutics Patents: Who Files, What They Claim
Concentrated but not locked. the top 5 assignees hold 32.6% of all 420 records in scope, and the top 10 hold 49.0% — leaving roughly half the field to a long tail of single- and low-volume filers. Filings moved from 35 in 2021 to 51 in 2024, a 46% rise over three years, with 2022 standing as the peak year recorded so far at 67. Treat the tail years as incomplete rather than declining.
- 1X CORP38
- 2ZYNGA INC36
- 3TERARECON INC25
- 4BETTERUP INC20
- 5MICROSOFT TECHNOLOGY LICENSING LLC18
See the full prescription digital therapeutics analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
How many companies actively hold patents in prescription digital therapeutics?
The assignee ranking behind this dataset covers 93 companies counted in records, drawn from 420 total records in scope. This is the complete ranked set the data endpoint returns, not a top-50 or top-100 cut, so it includes both high-volume filers and single-filing entrants. The top 5 of those 93 combine for 32.6% of all 420 records, and the top 10 combine for 49.0%, which means over half of filing activity is spread across the remaining companies rather than concentrated at the very top.
Is patent filing in this field still growing?
Yes, through the last year that can be treated as complete. Records rose from 35 in 2021 to 51 in 2024, a 46% increase over that three-year span, and 2022 was the single busiest year recorded so far at 67 filings. The 2025 and 2026 figures look lower only because publication lags filing by roughly 18 months, so those years are still filling in rather than reflecting an actual drop.
Are these patents mostly about the software or the drug itself?
Predominantly software and data architecture. G06F, the electric digital data processing class, appears on 37.1% of the 420 records in scope, and G16H healthcare informatics appears on 19.3%, compared with 14.5% for A61K medicinal preparations. That pattern indicates claim density sits on the app’s engagement tracking, clinical data handling and AI-model logic rather than on the therapeutic substance or protocol itself, since a record can carry more than one IPC class.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Prescription Digital Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.